Simple principles of clinical trials remain powerful

JAMA

Volumn 293, Issue 4, 2005, Pages 489-491

  Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; GLUCOSE; HEPARIN; INSULIN; POTASSIUM; REVIPARIN;

ACUTE HEART INFARCTION; CLINICAL TRIAL; COST MINIMIZATION ANALYSIS; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; FIBRINOLYTIC THERAPY; HEALTH CARE QUALITY; HEART MUSCLE ISCHEMIA; HUMAN; LONG TERM CARE; METABOLIC REGULATION; PATIENT CARE; PRIORITY JOURNAL; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 12544260666     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.4.489     Document Type: Editorial

References (20)

1. CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin- potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437-446.
2. CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA. 2005;293:427-436.
3. Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: part I. Circulation. 2002;106:1015-1021.
4. Peto R, Collins R, Gray R. Large-scale randomized evidence, large, simple trials and overviews of trials. J Clin Epidemiol. 1995;48:23-40.
5. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA. 2003;289:2545-2553.
6. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632.
7. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:1152-1156.
8. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292:89-96.
9. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. 1996;77:551-556.
10. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 1996;313:652-659.
11. Tunis SR. Why Medicare has not established criteria for coverage decisions. N Engl J Med. 2004;350:2196-2198.
12. Roe MT, Ohman EM, Pollack CV Jr, et al. Changing the model of care for patients with acute coronary syndromes. Am Heart J. 2003;146:605-612.
13. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academies Press; 1999.
14. Kohn LT, Corrigan JM, Donaldson MS, eds. To Err Is Human: Building a Safer Health Care System. Washington, DC: National Academies Press; 2000.
15. Brody BA. Ethical issues in clinical trials in developing countries. Stat Med. 2002;21:2853-2858.
16. Califf RM, Peterson ED, Gibbons RJ, et al; American College of Cardiology; American Heart Association. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol. 2002;40:1895-1901.
17. Vioxx: an unequal partnership between safety and efficacy. Lancet. 2004;364:1287-1288.
18. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance-lack of vigilance, lack of trust. JAMA. 2004;292:2647-2650.
19. Califf RM. Defining the balance of risk and benefit in the era of genomics and proteomics. Health Aff. 2004;23:77-87.
20. Yusuf S, Mehta SR, Diaz R, et al. Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. Am Heart J. 2004;148:1068-1078.